NIVF

NewGen records strong balance sheet with total assets of US$32.7 million Net profit attributable to shareholders of the Company of US$9.9 million BANGKOK, May 04, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group (NASDAQ: NIVF) (“NewGen” or the “Company”), a technology-driven, diversified growth company, today outlined several highlights of its fiscal year 2025 results and the steady progress of its continued strategic transformation. More information on NewGen’s results can be found in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2025, (the “2025 Annual Report”) which was filed with the U.S. Securities and Exchange Commission (the “SEC”) in April 2026. The full 2025 Annual Report can be viewed on the Company’s IR website at https://investors.newgenivf.com/financials/annual-reports. Key Financial and Operating Highlights Total assets as of December 31, 2025, were US$32.7 million, compared to US$3.6 million as of December 31, 2024. This represents total assets per share of US$135.9 as of December 31, 2025. Net profit attributable to shareholders of the Company for the year ended December 31, 2025, was US$9.9 million, primarily attributable to bargain purchase gain on the acquisition of the Company’s Nodexus and Microsort businesses. In July 2025, the Company successfully completed the acquisition of advanced cytometry intellectual property, which was subsequently independently valued at US$17.9 million by a “big-four” accounting firm, generating a total bargain purchase gain of US$19.2 million. In November 2025, the Company authorized a US$2 million share repurchase program, reflecting management’s confidence in the Company’s intrinsic value. The Company continued to make progress in the development of its diversification initiatives, including digital asset innovation through NewGenDigital and health supplements through NewGenSup. Mr. Siu Wing Fung Alfred, Founder, Chairman, and CEO of NewGen, commented, “Our fiscal year 2025 results reflect the successful execution of our ongoing strategic transformation. With total assets of over US$32 million and a significant profit for fiscal year 2025, we have demonstrated that our diversification strategy is delivering tangible results. We remain focused on building long-term shareholder value and believe our current financial position and growth trajectory provide a strong foundation for con...

By Michael Kim NASDAQ: NIVF READ THE FULL NIVF RESEARCH REPORT Ahead of 4Q25/full-year 2025 results likely to be announced later this month, we highlight several key strategic/financial announcements during the quarter: 1. Doubling down on UAE real estate project: In June 2025, NewGenIVF (NASDAQ: NIVF) announced plans to invest $45 million to acquire, develop, and resell real estate properties across the United Arab Emirates. Subsequently, the company acquired a plot of land in Ras Al Khaimah (RAK), the largest city and capital of the Emirate of Ras Al Khaimah, and established a joint venture with BNW Real Estate Development LLC, a real estate developer in Dubai, to help facilitate the design, construction, and marketing of the property. The project site is positioned in RAK’s Beach District, neighboring Al Marjan Island (the location of the Wynn Al Marjan Island resort set to open in early 2027), with plans to develop a luxury residential complex with 525,000+ square feet of Gross Floor Area (GFA) expected to be completed in 2028. Fast forward to December of last year, NIVF announced plans to exercise an option to convert the existing Joint Venture structure into a Joint Development structure, thereby transitioning project financing, development costs, pre-sales expenses, and financial escrow requirements to NewGenProperty, while upping the company’s profit participation potential related to the RAK project from ~$67 million to ~$123 million based on feasibility analyses. Under the new structure, the company plans to raise additional capital to fund NIVF’s incremental financial commitments. 2. Share repurchase authorization: As disclosed in November 2025, the Board of Directors authorized a share repurchase program. Terms of the authorization include the capacity to buy back $2 million of the company’s Class A Ordinary Shares over two years. Stepping back, share repurchases further enhance shareholder alignment, while reinforcing management’s conviction in prospective growth prospects, as well as the stock’s discounted valuation. Following the approval of 1:3 and 1:4 reverse stock splits in December 2025 and February 2026, respectively, the number of Class A Ordinary Shares outstanding was reduced to 568,323. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additiona...

By Michael Kim NASDAQ:NIVF Pre-market open on 12/2/25, NewGenIVF Group (NASDAQ:NIVF) reported financial results for the nine months ended September 30, 2025. Following our review of YTD results, we highlight the following key takeaways: 1. Financials mostly tracking in line with our full-year estimates: On a GAAP basis, NIVF reported net income of $17.5 million for the nine months ended 9/30/25, or $96.76 per basic share, representing a considerable turnaround from a net loss of $416K, or $205.97 per share, for the prior-year period. Much of the year-over-year improvement can be attributed to non-cash bargain purchase gains totaling $23.4 million related to the recent acquisitions of MicroSort technology and advanced cytometry intellectual property and equipment from Nodexus. For reference, our model calls for net income of $17.5 million for 2025. Focusing on the top line, NIVF generated year-to-date (YTD) total revenues of $3.3 million compared to $4.2 million for the first three quarters of 2024. After factoring in cost of revenues of $2.9 million, gross profit totaled $0.4 million for the first nine months of 2025 translating into a gross margin of 13.1%. YTD operating expenses totaled $6.2 million versus $1.4 million for the prior-year period, with much of the step up related to higher general & administrative costs associated with ongoing strategic initiatives to further expand and diversify the company’s portfolio of businesses (discussed next). Following through, NIVF reported a YTD operating loss of $5.8 million compared to $71K for the first three quarters of 2024. That said, the company generated $23.2 million of non-operating income for the nine months ended 9/30/25 compared to a loss of $347K for the prior-year period. Looking ahead, we will wait until NIVF reports full-year 2025 results to formally update our earnings model. 2. Plenty of growth catalysts: Beyond the core IVF business, management remains proactive in further building out the company’s portfolio of businesses, thereby enhancing growth prospects and sustainability – likely driving an outsized upward revaluation for the stock over time, we believe. a. Transformational acquisition: First and foremost, the company recently announced the execution of a non-binding term sheet related to a proposed merger with SAXA, Inc., an international holding company focused on high-value mining asse...

BANGKOK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or “the Company”), a technology-driven company building a diversified ecosystem across fertility technology, digital assets, and real estate development, today reported its unaudited financial results for the nine months ended September 30, 2025. Financial Highlights for the Nine Months Ended September 30, 2025 Net income attributable to the shareholders of the Company was $17.5 million, a significant improvement from a net loss of $416,400 in the same period of 2024. This was primarily due to a non-cash, bargain purchase gain recognized on the acquisition of Nodexus and Microsort businesses. Basic earnings per share was $96.76 for the nine months ended September 30, 2025 while losses per share for the nine months ended September 30, 2024 was $205.97. Net book value per share improved to $66.75 from negative net book value as of December 31, 2024, representing a significant balance sheet transformation driven by strategic acquisitions of high-value intellectual property assets. Business Highlights for the Nine Months Ended September 30, 2025 The Company has made significant progress in executing its strategic pivot and diversification strategy throughout 2025. Key initiatives and achievements demonstrating this progress include: Transformative Acquisitions: The Company completed two key acquisitions. On February 28, 2025, the Company acquired the MicroSort® sperm-sorting technology, enhancing its capabilities in the fertility services market. The acquisition also resulted in a prior bargain purchase gain of $4.28 million based on an independent valuation report. On July 29, 2025, the Company acquired advanced cytometry intellectual property and equipment from Nodexus. An independent valuation by a “big-four” accounting firm received in October 2025 confirmed a fair value of $17.9 million for the IP, resulting in a total bargain purchase gain of $19.16 million. This acquisition is central to the Company’s pivot towards a high-margin, technology-licensing business model. 2025 Debt Financing: On April 1, 2025, the Company entered into a Securities Purchase Agreement for the issuance of senior convertible notes with an aggregate principal amount of up to $28.8 million. The first tranche of $3.2 million was received on June 3, 2025, providing capital to fund our strategic...